Treatment
Treatment Of Physician's Choice clinical trials
We’re tracking 46 recruiting studies that include Treatment Of Physician's Choice, each written for real people, not researchers, below.
Recruiting studies
- NCT06268652RecruitingPhase 3
Personalized treatment guided by lab-grown tumor samples for advanced breast cancer
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
Guangzhou, None SelectedAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Springdale, ArkansasAges 18 years+ - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Birmingham, AlabamaAges 18 years+ - NCT06035016Recruiting
Pyrotinib and capecitabine after surgery for HER2+ breast cancer
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
Beijing, Beijing MunicipalityAges 18–75 - NCT06079983RecruitingPhase 3
JSKN003 vs. doctor's choice for HER2-low breast cancer
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT06383767RecruitingPhase 3
A study of ESG401 for advanced HR+/HER2- breast cancer
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06692166RecruitingPhase 3
New drug vs standard chemo for advanced cervical cancer
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
BeijingAges 18–75 - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT07227233RecruitingPhase 2
AI-guided retrial of CDK4/6 inhibitors for advanced breast cancer
This trial tests whether an artificial intelligence (AI) tool can help doctors decide if it is safe and effective to give you a second course of a CDK4/6 inhibitor drug (like palbociclib, ribociclib, or abemaciclib) plus hormone therapy for advanced (unresectable or metastatic) HR+/HER2- breast cancer. The goal is to only treat people whose cancer is likely to respond based on a special AI analysis of their tumor tissue.
La Jolla, CaliforniaAges 18 years+ - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07533123RecruitingPhase 3
New drug JSKN016 for triple-negative breast cancer after chemotherapy
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
Guangzhou, GuangdongAges 18–75 - NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06651970RecruitingPhase 4
Acalabrutinib for chronic lymphocytic leukemia with heart problems
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
Charlotte, North CarolinaAges 18–130 - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+
What Treatment Of Physician's Choice is being studied for
Conditions with recruiting Treatment Of Physician's Choice studies.
Common questions
- Are there clinical trials studying Treatment Of Physician's Choice?
- Yes. Clin2 currently lists 46 recruiting studies that include Treatment Of Physician's Choice, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Treatment Of Physician's Choice trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Treatment Of Physician's Choice an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Treatment Of Physician's Choice or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.